-
Media ReleaseNovartis ranks first in 2024 Access to Medicine Index
-
Story
Negative impact of the IRA on patient access to innovative treatments -
Story
A partnership against epilepsy -
Story
Beacon of Hope lights the way for a more equitable future -
Media ReleaseSandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio
-
Media ReleaseSandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
-
Media ReleaseNovartis publie l’invitation à l’AGE et la brochure d’information aux actionnaires. Sandoz publie le prospectus de cotation avant le vote sur la proposition de scission
-
Media ReleaseNovartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off vote
-
Media ReleaseNovartis publiziert Einladung und Aktionärsbroschüre zur ausserordentlichen Generalversammlung. Sandoz veröffentlicht den Kotierungsprospekt im Vorfeld der Abstimmung zum vorgeschlagenen Spin-off
-
Media ReleaseSandoz announces plans to build a Biosimilar Technical Development Center in Slovenia to support future growth of biosimilar pipeline
-
Media ReleaseSandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines
-
Media ReleaseSandoz presents compelling investment proposition as standalone company at Capital Markets Day